Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anan Bzami

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Gates Open Research|May 18, 2026
Qualification of a quantitative stability indicating potency assay for mRNA-LNP vaccine candidatesAnan Bzami, Marcus Estrada, Tim Schofield, et al.
Vaccine|January 19, 2023
Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentrationMarcus R Estrada, Anan Bzami, Elizabeth B Norton, et al.
Vaccine: X|August 27, 2024
Development of multidose thermotolerant formulations of a vector-based Covid-19 vaccine candidate, NDV-HXP-S in different product formats: Stability and preservative efficacy studyAnan Bzami, Changcheng Zhu, Marcus Estrada, et al.
Human Vaccines & Immunotherapeutics|February 19, 2024
Development of a quantitative ELISA for SARS-CoV-2 vaccine candidate, NDV-HXP-S, with CpG 1018® adjuvantMarcus Estrada, Changcheng Zhu, Anan Bzami, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Gates Open Research|May 18, 2026
Qualification of a quantitative stability indicating potency assay for mRNA-LNP vaccine candidatesAnan Bzami, Marcus Estrada, Tim Schofield, et al.
Vaccine|January 19, 2023
Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentrationMarcus R Estrada, Anan Bzami, Elizabeth B Norton, et al.
Vaccine: X|August 27, 2024
Development of multidose thermotolerant formulations of a vector-based Covid-19 vaccine candidate, NDV-HXP-S in different product formats: Stability and preservative efficacy studyAnan Bzami, Changcheng Zhu, Marcus Estrada, et al.
Human Vaccines & Immunotherapeutics|February 19, 2024
Development of a quantitative ELISA for SARS-CoV-2 vaccine candidate, NDV-HXP-S, with CpG 1018® adjuvantMarcus Estrada, Changcheng Zhu, Anan Bzami, et al.
Pageof 1